Clinical Trials

Clinical trials currently available via Treatment Center / Clinical Trials directory.

Clinical Trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC

Brief Summary:

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.


Clinical Trials

Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Brief Summary:

Clinical Trials

Dose-Escalation Trial Evaluating CPI-818

Brief Summary:

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.


Clinical Trials

Mogamulizumab Q4week Dosing

Brief Summary:

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.


Clinical Trials

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB MF and SS

Brief Summary:

Clinical Trials

Lacutamab - TELLOMAK Study

An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of lacutamab (IPH4102) alone or in combination with chemotherapy in patients with advanced t-cell lymphoma


Clinical Trial Name: IPH4102-201 / TELLOMAK study


Clinical Trial Description:

Clinical Trials

TTI-621 - Study

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides


Brief Summary

Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.